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ABSTRACT
Pancreatic cancer, one of the most lethal cancers, has very poor 5-year survival 
partly due to gemcitabine resistance. Recently, it was reported that chemotherapeutic 
agents may act as stressors to induce adaptive responses and to promote 
chemoresistance in cancer cells. During long-term drug treatment, the minority of 
cancer cells survive and acquire an epithelial-mesenchymal transition phenotype with 
increased chemo-resistance and metastasis. However, the short-term response of most 
cancer cells remains unclear. This study aimed to investigate the short-term response 
of pancreatic cancer cells to gemcitabine stress and to explore the corresponding 
mechanism. Our results showed that gemcitabine treatment for 24 hours enhanced 
pancreatic cancer cell invasion. In gemcitabine-treated cells, HAb18G/CD147 was up-
regulated; and HAb18G/CD147 down-regulation or inhibition attenuated gemcitabine-
enhanced invasion. Mechanistically, HAb18G/CD147 promoted gemcitabine-enhanced 
invasion by activating the EGFR (epidermal growth factor receptor)-STAT3 (signal 
transducer and activator of transcription 3) signaling pathway. Inhibition of EGFR-
STAT3 signaling counteracted gemcitabine-enhanced invasion, and which relied on 
HAb18G/CD147 levels. In pancreatic cancer tissues, EGFR was highly expressed and 
positively correlated with HAb18G/CD147. These data indicate that pancreatic cancer 
cells enhance cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. Our 
findings suggest that inhibiting HAb18G/CD147 is a potential strategy for overcoming 
drug stress-associated resistance in pancreatic cancer.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a highly 
aggressive solid tumor and the fourth cause of cancer-related 
death [1]. Despite new therapeutic strategies, PDAC has a 
5-year survival of less than 5% and a median survival of just 
over 6 months [2]. Surgical resection is rarely possible for 
advanced PDAC; thus, the genotoxic DNA-damaging agent 
gemcitabine has historically been the first-line therapeutic 
agent. However, most patients with unresectable PDAC 
either do not respond or respond transiently and modestly 
to gemcitabine and ultimately die because of therapeutic 
resistance and subsequent metastatic disease [3]. Therefore, 
investigating the cellular and molecular mechanisms involved 
in gemcitabine resistance is urgently needed for developing 
successful treatments for pancreatic cancer.
Currently, chemo-radiotherapy is the standard 
cytocidal therapy, which primarily concerns on the ability 
of a drug to induce cancer cell death. Researchers have 
focused on developing therapeutic agents that are more 
effective to eliminate the maximum number of tumor 
cells [4]. Unfortunately, although great achievements 
were reached in the beginning, recent studies have 
revealed that current therapeutic approaches that aim to 
eradicate the primary tumor may only have short-term 
benefits and eventually lead to increased tumor cells 
                   Research Paper
Oncotarget62178www.impactjournals.com/oncotarget
resistance and metastasis [4, 5]. For example, multiple 
metastases are induced by the VEGFR kinase inhibitor 
sunitinib/SU11248 or VEGFR-specific antibodies [6, 7], 
and the BRAF inhibitor PLX4720 induces metastasis 
in RAS- or BRAF-mutant melanoma [8]. We have also 
observed post-radiation tumor recurrence in pancreatic 
cancer [9]. The failure of current therapeutic approaches 
is partly due to a lack of understanding of the molecular 
signaling pathways utilized by cancer cells to actively 
respond to therapeutic pressures [4, 10]. Accumulating 
evidence has indicated that chemo-radiotherapy may not 
kill all the cancer cells but may act as a stressor on the 
surviving cells, inducing active counter-defense responses 
that protect cells from drug stress and lead to drug 
resistance through selection [11, 12]. Thus, elucidating the 
mechanisms by which tumor cells counteract drug stress 
may contribute to the development of therapeutic agents 
that reverse gemcitabine resistance.
Based on the severity and duration of stress, drugs 
can force cells to adapt, escape, or die. Specifically, 
cells can succumb to drug stress via apoptosis when the 
stress is harsh and the protective response is unsuccessful 
(apoptosis), cells can survive and adjust to the original site 
when the stress is persistent and less severe via a series of 
protective responses (stay and adapt), or cells can move 
from a hostile niche to a more favorable one when the 
stress is less severe without eliciting a protective response 
(avoid and escape) [5, 10]. Due to genetic and epigenetic 
instability, malignant tumor cells are predisposed to resist 
drug stress via adaptation procedures or stress avoidance 
mechanisms. Epithelial-mesenchymal transition (EMT), 
a hallmark of cancer metastasis, is a typical adaptive 
response to therapeutic induced-DNA damage. EMT 
influences the cellular sensitivity to gemcitabine and 
endows pancreatic cancer cells with a drug resistance 
phenotype [13]. Chemotherapy-induced cell death 
generally occurs with 48 hours of treatment [14]; however, 
EMT confers to improved cell survival over a long-term 
adaptation, which is usually detectable after 3-4 days of 
treatment. Simply interfering with EMT cannot effectively 
alter the treatment response, as EMT occurs after 
tumor cell death decisions are made. Thus, identifying 
the short-term cellular response to drug stress and 
determining whether this short-term response promotes 
chemoresistance in pancreatic cancer are important.
HAb18G/CD147, which belongs to the CD147 
(also called EMMPRIN or basigin) family, is a cancer-
associated biomarker for detection [15] and an effective 
target for treatment [16, 17]. Licartin, an antibody against 
HAb18G/CD147, has been approved to treat primary 
hepatocellular carcinoma and to prevent tumor recurrence 
after liver transplantation or radiofrequency ablation 
in China [16, 17]. Our previous studies have shown 
that HAb18G/CD147 facilitates cancer metastasis and 
progression by inducing MMP secretion and cell motility 
[18] and that HAb18G/CD147 promotes chemoresistance 
by functioning as a novel unfolded protein response 
transducer in response to anti-cancer drug-induced 
cellular stress [19]. HAb18G/CD147 expression also 
correlates with other cellular stress responses, such as 
EMT [20], autophagy [21], and anoikis resistance [22, 
23], suggesting that HAb18G/CD147 may involve in 
cellular responses to drug stress. Recently, others and we 
reported that CD147 is overexpressed in highly aggressive 
pancreatic cancer and acts as a novel upstream activator 
in STAT3-mediated pancreatic tumor development [24, 
25]. CD147 knock-down via RNA interference increases 
the chemosensitivity of human pancreatic cancer cells to 
gemcitabine [26]. Anti-CD147 antibodies have been used 
as positron emission tomography probes for imaging [27] 
or in gemcitabine-based combination therapy [28] for 
pancreatic cancer. However, whether HAb18G/CD147 is 
involved in the short-term stress response of pancreatic 
cancer cells to gemcitabine is unclear.
This systematic study aimed to investigate the short-
term response of pancreatic cancer cells to gemcitabine, 
to explore the role of HAb18G/CD147 in this response 
and to determine the corresponding molecular mechanism 
of action. In response to short-term gemcitabine stress, 
pancreatic cancer cells accelerate invasion by up-
regulating HAb18G/CD147 expression and activating 
HAb18G/CD147 downstream of EGFR-pSTAT3 
signaling. Thus, the activation of early cellular responses 
protects pancreatic cancer cells from drug stress-induced 
cell death and may facilitate tumor resistance to therapy. 
Blocking the short-term response by inhibiting the 
HAb18G/CD147 signaling pathway may provide a 
novel therapeutic strategy for overcoming gemcitabine 
resistance in pancreatic cancer.
RESULTS
Gemcitabine enhances the migration and 
invasion of pancreatic cancer cells
We first determined the chemo-sensitivity of 
pancreatic cancer cell lines to gemcitabine, which was 
assayed by cell growth inhibition at 72 hours. The IC50 
(drug concentration that caused 50% growth inhibition) 
values for MIA PaCa-2 and PANC-1 cells were 0.03 ± 
0.01 μM and 1.62 ± 0.91 μM, respectively (Supplementary 
Figure S1A). For an optimal time course of gemcitabine 
cytotoxicity, we treated MIA PaCa-2 cells for 8-72 hours 
at concentrations of 0.1–10 μM. The cell relative viability 
of all dosages was above 80% within 8-24 hours but was 
below 60% beyond 24 hours (Supplementary Figure S1B). 
Thus, to explore the short-term cellular response to drug 
stress, we investigated the migration and invasion by 
treating cells with 0.1-10 μM gemcitabine for 24 hours. 
As PANC-1 cells were more resistant to gemcitabine, we 
increased the minimum and maximum gemcitabine doses 
to 1 μM and 100 μM. At the 24-hour time point when 
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the cells were analyzed for migration and invasion, the 
cell viability at different gemcitabine concentrations was 
above 90% (Supplementary Figure S1C). However, the 
migration potential of gemcitabine-treated cells increased 
significantly in a dose-dependent manner compared to 
untreated cells, with significant increases occurring at 
10 μM for MIA PaCa-2 and at 10 μM and 100 μM for 
PANC-1 cells (Figure 1). A similar increasing trend was 
also observed in the invasion assay, with more significant 
enhancement occurring at the same concentration. At 1 
μM, gemcitabine did not significantly stimulate migration 
but did enhance invasion in both PANC-1 and MIA 
PaCa-2 cells, indicating that invasion potential was a more 
obvious response to gemcitabine stress than migration. We 
then adopted in vitro invasion assay as a representative 
means to explore the short-term cellular response to 
gemcitabine. Together, our results showed that pancreatic 
cancer cells responded to short-term gemcitabine treatment 
by enhancing migration and invasion, with more migration 
and invasion occurring at higher concentration, indicating 
a potential early active escape mechanism in response to 
gemcitabine stress.
Figure 1: Gemcitabine enhances the migration and invasion of pancreatic cancer cells. MIA PaCa-2 and PANC-1 cells 
were treated with 0, 0.1, 1, 10, or 100 μM gemcitabine for 24 hours and then were seeded on non-coated (migration) and Matrigel-coated 
(invasion) upper chambers. Cells that migrated/invaded to the lower surface of the filter were fixed, stained, imaged, and counted in 10 
random fields. Bars = 500 μm as indicated. **P < 0.01; ***P < 0.001 compared with control.
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HAb18G/CD147 is required for gemcitabine-
enhanced migration and invasion in pancreatic 
cancer cells
Recently, HAb18G/CD147 was shown to be highly 
expressed in pancreatic cancer cells; and HAb18G/CD147 
is widely involved in metastasis and chemoresistance and 
correlates with cellular stress responses [24, 26]. Therefore, 
we explored the role of HAb18G/CD147 in gemcitabine-
enhanced migration/invasion by exposing pancreatic 
cancer cells to 0-10 μM gemcitabine for 24 hours. As 
shown in Figure 2A and 2B and in Supplementary Figure 
S2A, gemcitabine up-regulated HAb18G/CD147 protein 
expression in a dose-dependent manner in both pancreatic 
cancer cell lines, with the maximal enhancement occurring 
at 10 μM gemcitabine. The up-regulation of HAb18G/
CD147 protein expression was also time-dependent; 
increased HAb18G/CD147 protein expression occurred 
as early as 12 hours, before the increases in migration and 
invasion (Figure 2C). However, HAb18G/CD147 mRNA 
expression was increased as late as 24 hours, indicating 
a non-transcription-based mechanism for up-regulating 
HAb18G/CD147 protein levels at 12 hours.
To further determine whether HAb18G/CD147 
is required for gemcitabine-enhanced migration and 
invasion, we adopted a loss-of-function strategy using 
the pLKO lentiviral vector [24]. When HAb18G/CD147 
expression was effectively silenced (typically 60-80% 
reduction in protein expression), which was validated by 
western blot and flow cytometry, gemcitabine-enhanced 
invasion was significantly attenuated in both PANC-1 
and MIA PaCa-2 cells (Figure 2D, Supplementary Figure 
S2B). Moreover, the anti-HAb18G/CD147 monoclonal 
antibody HAb18IgG (30 μg/mL) significantly counteracted 
gemcitabine-enhanced invasion in both cell lines (Figure 
2E, Supplementary Figure S2C). These results strongly 
suggest that HAb18G/CD147 is required for gemcitabine-
enhanced migration/invasion in pancreatic cancer cells 
and that HAb18G/CD147 correlates with the cellular 
response to gemcitabine stress and the related resistance. 
HAb18IgG effectively abolished gemcitabine-enhanced 
migration/invasion, suggesting the therapeutic potential 
of this antibody in gemcitabine-resistant pancreatic cancer.
EGFR-STAT3 signaling is involved in 
gemcitabine-enhanced migration and invasion
We recently reported that HAb18G/CD147 is an 
upstream activator of STAT3 signaling in pancreatic 
cancer; the STAT3 pathway is a critical pathway that is 
activated in gemcitabine-resistant cells [24, 29]. STAT3 
activity is also necessary for pancreatic cancer cell 
invasion via MMP7 [30]. To investigate whether pSTAT3 
is also involved in gemcitabine-enhanced migration 
and invasion in pancreatic cancer cells, we examined 
phosphorylated STAT3 (pSTAT3) and total STAT3 
protein levels after gemcitabine treatment. The protein 
levels of pSTAT3, but not of total STAT3, increased in 
a dose-dependent manner in both pancreatic cancer cell 
lines after 24 hours of gemcitabine treatment (Figure 
3A). The pSTAT3-specific inhibitor WP1066 inhibited 
cell invasion in a dose-dependent manner, with maximal 
inhibition occurring at 1 μM (Supplementary Figure 
S3A). Moreover, 1 μM WP1066 significantly abolished 
gemcitabine-enhanced invasion in both pancreatic cancer 
cell lines, although the degree of inhibition differed 
(Figure 3B). By contrast, WP1066 treatment resulted in 
greater suppression of gemcitabine-related invasion in 
MIA PaCa-2 cells (45%) than in PANC-1 cells (28%), 
consistent with the fact that the pSTAT3 expression level 
is higher in MIA PaCa-2 cells than in PANC-1 cells [24]. 
Therefore, pSTAT3 appears to be involved in gemcitabine-
enhanced migration and invasion of pancreatic cancer 
cells.
In Figures 1, 2D and 2E, we noticed that 
gemcitabine-resistant EGFR-mutant PANC-1 cells 
exhibited greater gemcitabine-enhanced invasion than 
gemcitabine-sensitive EGFR-wild type MIA PaCa-2 cells, 
indicating that EGFR might be related to gemcitabine-
enhanced invasion. As STAT3 is activated by EGFR [31], 
we examined whether EGFR is involved in gemcitabine-
enhanced invasion by activating STAT3. As shown in 
Figure 3A, a dose-dependent increase in pEGFR, together 
with pSTAT3, was observed in 0-10 μM gemcitabine-
treated pancreatic cancer cells. However, unlike pEGFR, 
total EGFR was not changed upon gemcitabine treatment. 
Moreover, time-dependent increases in pEGFR and 
pSTAT3 were observed in MIA PaCa-2 cells as early as 4 
and 6 hours, respectively; both were later than the increase 
in CD147, which occurred at 2 hours (Figure 3C). Treating 
cells with the EGFR inhibitor PD153035 resulted in dose-
dependent inhibition of pSTAT3 levels, but not total 
STAT3 levels (Supplementary Figure S3B), indicating 
that EGFR is involved in gemcitabine-enhanced invasion 
via STAT3. Thus, the EGFR-STAT3 signaling pathway 
contributes to gemcitabine-enhanced invasion.
HAb18G/CD147 activates pSTAT3 signaling via 
EGFR
As shown above, HAb18G/CD147 and EGFR activate 
STAT3 signaling, contributing to gemcitabine-enhanced 
invasion. Therefore, we examined whether HAb18G/CD147 
activates gemcitabine-enhanced pSTAT3 signaling via EGFR 
or vice versa. As the time-dependent increase in pEGFR 
occurred later than that in HAb18G/CD147, we deduced 
that HAb18G/CD147 might activate pSTAT3 signaling 
via EGFR. To elucidate this possibility, we knocked down 
HAb18G/CD147 expression using siCD147 and then treated 
cells with or without PD153035. As shown in Figure 3D, 
pSTAT3 levels greatly decreased in both siCD147- and 
PD153035-treated cells; and pSTAT3 levels further decreased 
Oncotarget62181www.impactjournals.com/oncotarget
Figure 2: HAb18G/CD147 is required for gemcitabine-enhanced migration and invasion of pancreatic cancer cells. 
A. Flow cytometric analysis of the membrane expression of HAb18G/CD147 in pancreatic cancer cells treated with different doses of 
gemcitabine (0, 0.1, 1, or 10 μM) for 24 hours. Cells were labeled with FITC-conjugated anti-human CD147 antibody, and isotype-matched 
mouse immunoglobulin was used as a control. B. Western blot analysis of HAb18G/CD147 protein levels in pancreatic cancer cells treated 
with different doses of gemcitabine (Gem) (0, 0.1, 1, or 10 μM) for 24 hours. a-tubulin was included as a loading control. C. mRNA 
(qPCR) and protein (western) levels of HAb18G/CD147 in 10 μM gemcitabine-treated MIA PaCa-2 cells at different time points (0,12, 
24 hours). D. In vitro invasion assay of HAb18G/CD147 knock-down cells treated with or without gemcitabine (10 μM, 24 hours). The 
photomicrographs at the top illustrate representative fields of invaded cells. Knock-down efficiency was confirmed by immunoblot analysis 
(bottom left). The number of invaded cells was calculated; the data are presented in a histogram (bottom right). NTC, non-target shRNA 
control; A6, CD147 shRNA. E. In vitro invasion assay of pancreatic cancer cells treated with gemcitabine (10 μM, 24 hours) alone or in 
combination with 30 μg/mL HAb18IgG.
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Figure 3: EGFR-STAT3 signaling is involved in gemcitabine-enhanced migration and invasion. A. Western blot analysis 
of pSTAT3, STAT3, pEGFR, and EGFR protein levels in pancreatic cancer cells treated with different doses of gemcitabine (0, 0.1, 1, or 10 
μM) for 24 hours. B. In vitro cell invasion of pancreatic cancer cells treated with gemcitabine (10 μM, 24 hours) alone or in combination 
with WP1066 (1 μM, 24 hours). C. Western blot analysis of pSTAT3, STAT3, pEGFR, and EGFR protein levels in 10 μM gemcitabine-
treated pancreatic cancer cells at different time points (0, 2, 4, 6, 14, or 24 hours). D. Western blot analysis of pSTAT3, STAT3 and CD147 
protein levels in pancreatic cancer cells treated with CD147 siRNA and 10 μM PD153035 alone or in combination. Silencer negative 
control siRNA (sncRNA) was used as a negative control.
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in response to combined siCD147 and PD153035 treatment, 
suggesting that the PD153035-induced decrease in the 
pSTAT3 level correlated with HAb18G/CD147 expression. 
As the CD147 activation and knock-down influenced the 
pEGFR levels accordingly (Figure 3D), EGFR-activated 
pSTAT3 signaling depended on HAb18G/CD147 levels.
To further explore the relationship between HAb18G/
CD147 and EGFR, we tested whether CyPA, a natural ligand 
for HAb18G/CD147 [24], could up-regulate EGFR levels 
in pancreatic cancer cells. As shown in Figure 4A, CyPA 
stimulation caused dose- and time-dependent increases 
in pEGFR levels. Next, we determined whether the above 
CyPA effects were HAb18G/CD147 dependent or not 
by knock-down or knock-in of CD147. Both EGFR and 
pEGFR protein levels were reduced after HAb18G/CD147 
knock-down; moreover, CyPA-induced pEGFR protein 
expression was attenuated by HAb18G/CD147 knock-down 
(Figure 4B). In contrast, EGFR and pEGFR protein levels 
were significantly increased by HAb18G/CD147 knock-
in in HEK293 cells, indicating that the CyPA-mediated 
increase in pEGFR/EGFR protein expression correlated with 
HAb18G/CD147 levels. Using immunofluorescence staining, 
we observed that both HAb18G/CD147 and EGFR were 
evenly distributed on the cell membrane in control vector-
transfected PANC-1 NTC cells. However, EGFR membrane 
expression was significantly reduced after HAb18G/CD147 
knock-down in A6 cells (Figure 4C). These results suggest 
that HAb18G/CD147 activates EGFR protein expression and 
phosphorylation.
To evaluate whether HAb18G/CD147 functionally 
influences EGFR in pancreatic cancer cells, we 
performed cell growth assays after exposing cells to 
CyPA and the EGFR inhibitor gefitinib. Gefitinib (80 
μM) significantly inhibited CyPA-induced cell growth 
to the level of control in both cell lines (P = 0.0027 and 
P = 0.0403 for MIA PaCa-2 and PANC-1, respectively, 
Figure 4D). Furthermore, the cell growth inhibition by 
gefitinib correlated with HAb18G/CD147 levels: cell 
growth decreased 1.96-3.95 fold in cells with HAb18G/
CD147 knock-down and increased 1.62-fold in cells with 
HAb18G/CD147 knock-in (Figure 4E), indicating that 
EGFR acts downstream of HAb18G/CD147 in pancreatic 
cancer cells. Together, these results suggest that HAb18G/
CD147 contributes to gemcitabine enhanced-invasion via 
activating EGFR-STAT3 signaling.
HAb18G/CD147 and EGFR are co-
overexpressed in human pancreatic cancer
To investigate whether the expression levels of 
HAb18G/CD147 and EGFR are associated in human 
pancreatic cancer, we firstly analyzed EGFR mRNA 
expression levels in 7 pairs of pancreatic cancer and 
adjacent non-tumor tissues from patients with pancreatic 
cancer. As indicated in Figure 5A, EGFR mRNA levels 
in pancreatic tumor tissues increased 2.33-fold on 
average compared to those in adjacent non-tumor tissues 
(P = 0.0973, n = 7). Moreover, EGFR mRNA levels 
significantly correlated with HAb18G/CD147 mRNA 
levels (Spearman r = 0.8829, P = 0.0123, Figure 5B).
We then analyzed EGFR protein expression in 
179 pancreatic tissues. In a pancreatic tissue microarray 
(TMA) of 179 samples, EGFR was positively expressed in 
20.8% (10/48) of normal pancreatic tissues and in 71.4% 
(5/7), 66.7% (14/21) and 78.6% (81/103) of the chronic 
pancreatitis, pancreatic preneoplasia and PDAC samples, 
respectively (Figure 5C, Table 1). The positive ratios 
of EGFR expression in chronic pancreatitis, pancreatic 
preneoplasia and PDAC were significantly higher than 
those in adjacent non-tumor tissues (P = 0.019, P < 0.001, 
and P < 0.001, respectively). Moreover, the intense staining 
ratio of EGFR in PDAC (40.8%) increased by 1.43- and 
2.15-fold compared with chronic pancreatitis (28.6%) and 
pancreatic preneoplasia (19.0%), respectively, although 
these differences did not reach statistical significance.
Next, we analyzed the co-expression of EGFR 
and HAb18G/CD147 in 47 normal pancreas and 102 
pancreatic cancer tissues with positive staining for both 
antigens. As indicated in Table 2, a significantly higher 
incidence of high expression of both EGFR and HAb18G/
CD147 was found in pancreatic cancer tissues compared 
with normal tissues (71.57% [73/102] vs. 17.02% [8/47], 
P < 0.001). The incidence of HAb18G/CD147highEGFRhigh 
(71.57%) in pancreatic cancer tissues was significantly 
higher than that of HAb18G/CD147lowEGFRlow (4.90%), 
HAb18G/CD147high (15.69%), or EGFRhigh (7.84%) (P < 
0.001 for all three groups). Furthermore, high HAb18G/
CD147 expression was significantly correlated with high 
EGFR expression (Spearman r = 0.3086, P = 0.0016), 
suggesting that the high expression levels of both 
HAb18G/CD147 and EGFR might have important roles 
in promoting pancreatic cancer progression.
HAb18G/CD147 is essential for gemcitabine-
enhanced invasion in mice
Above studies showed that short-term gemcitabine 
exposure can rapidly enhance in vitro cell invasion 
through up-regulating CD147 expression. Whether 
this scenario actually existed in vivo is unclear yet. 
Therefore, we examined the response of tumor cells to 
gemcitabine chemotherapy in mice. MIA PACa-2 NTC 
or CD147 knock-down A6 cells were inoculated into 
five- to six-week-old female nude mice subcutaneously. 
When tumors reached a mean volume of 100mm3, we 
treated tumor-bearing mice with 100mg/kg gemcitabine 
or saline. 24 hours later, tumor cells were isolated to 
assess cell invasion. Our results showed that MIA PaCa-
2 NTC cells from the gemcitabine-treated mice gained 
significantly increased invasion ability and significantly 
increase of CD147 membrane expression when compared 
with MIA PaCa-2 NTC cells from the vehicle-treated 
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Figure 4: HAb18G/CD147 activates EGFR-pSTAT3 signaling in pancreatic cancer cells. A. Western blot analysis of pEGFR 
and EGFR protein levels in serum-starved PANC-1 cells treated with CyPA for different time points (right) at different concentrations 
(left). Treatment with phosphate-buffered saline was used as a control. B. Western blot analysis of pEGFR and EGFR protein levels in 
serum-starved HAb18G/CD147 knock-down or knock-in cells treated with or without 100 nM CyPA for 30 min. C. Immunofluorescence 
co-labeling of HAb18G/CD147 (green) and EGFR (red) in HAb18G/CD147 knock-down PANC-1 cells. Magnification: 400×. D. Cell 
growth assay in MIA PaCa-2 and PANC-1 cells treated with or without the EGFR inhibitor gefitinib (80 μM, 72 hours) and/or CyPA (100 
nM, 30 min). E. Cell growth assay in HAb18G/CD147 knock-down or knock-in cells after treatment with the EGFR inhibitor gefitinib 
(80 μM, 48 hours).
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Figure 5: HAb18G/CD147 and EGFR are co-expressed in human pancreatic tumors. A. EGFR mRNA levels in 7 pairs 
of PDACs and adjacent non-tumor tissues. Levels were normalized against 18S RNA levels. B. Correlation analysis between EGFR and 
HAb18G/CD147 mRNA expression in 7 PDACs. C. Immunohistochemical staining of EGFR protein levels in normal pancreas and PDAC. 
Representative morphology of EGFR immunostaining in normal pancreatic tissues (No. 10 and No. 21) and in pancreatic cancer tissues 
(No. 10 and No. 25) is shown. Magnification: 600×. D. Boyden chamber assay of cell invasion and E. flow cytometric analysis of HAb18G/
CD147 membrane expression in tumor cells isolated from mice. F. A proposed working model for gemcitabine-enhances pancreatic cancer 
cell invasion via HAb18G/CD147-EGFR-pSTAT3 signaling.
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mice (Figure 5D and 5E). On the contrary, CD147 knock-
down A6 cells from the gemcitabine-treated mice and the 
vehicle-treated mice almost lost the invasion ability. This 
result provides the in vivo evidence that gemcitabine-
treatment induces an increase of the invasion ability of 
tumor cells, and HAb18G/CD147 plays an important role 
in tumor cells evasion of gemcitabine stress in vivo.
DISCUSSION
In this study, we found that pancreatic cancer 
cells escape short-term gemcitabine-enhanced stress by 
increasing invasion rather than by succumbing to stress-
induced death or in situ adaptive survival. In response to 
short-term gemcitabine stress, HAb18G/CD147 was up-
regulated and promoted invasion. Inhibition or blocking 
HAb18G/CD147 via knock-down or antibody treatment 
attenuated gemcitabine-enhanced invasion. We also found 
that the EGFR-STAT3 signaling pathway was activated 
in response to short-term gemcitabine treatment and 
that inhibition of EGFR-STAT3 signaling counteracted 
gemcitabine-enhanced invasion, which correlated with 
HAb18G/CD147 levels. In pancreatic cancer tissues, high 
HAb18G/CD147 expression was significantly correlated 
with high EGFR expression, and high expression of both 
HAb18G/CD147 and EGFR was observed in 71.57% of 
pancreatic cancer samples. Taken together, these data 
revealed that pancreatic cancer cells actively defend 
Table 1: EGFR expression in pancreatic tissues
Groups
EGFR expression levelsa P valueb
Low High
























































aEGFR expression levels were classified as 0 (no staining), 1 (light staining), 2 (intermediate staining) or 3 (intense 
staining).
bEstimated using the χ2 test compared with normal tissue after dividing the samples into low- and high-expression groups. 
The low-expression group includes cases with a staining intensity score of 0; the high-expression group includes cases with 
staining intensity scores of 1-3. N, not detected.
Table 2: HAb18G/CD147 and EGFR co-expression in pancreatic tissues
Group Normal Cancer
CD147lowEGFRlow 5/47 10.64% 5/102 4.90%
CD147highEGFRlow 33/47 70.21% 16/102 15.69%
CD147lowEGFRhigh 1/47 2.13% 8/102 7.84%
CD147highEGFRhigh 8/47 17.02% 73/102 71.57%*
Pearson r = 0.3086 (95% confidence interval: 0.1157–0.4792), P = 0.0016.
* Estimated by χ2 test compared with normal pancreas tissues.
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against gemcitabine stress by accelerating cell invasion 
via activating HAb18G/CD147-EGFR-pSTAT3 signaling. 
An antibody against HAb18G/CD147 could be a potential 
therapeutic agent for overcoming gemcitabine stress-
associated resistance in pancreatic cancer.
Our results and others’ show that current 
therapies, such as the genotoxic DNA-damaging agent 
gemcitabine, show efficacy in early stages of cancer 
but may increase oncogenic characteristics such as 
invasiveness and metastasis later on [32]. Normally, the 
response to therapy (inhibition of growth and/or survival 
of cancer cells) and selection for resistance will occur 
simultaneously [33]. While therapy-induced killing of 
cancer cells results in therapeutic response and cancer 
remission, they simultaneously select for drug resistance 
[11, 12]. These resistant cells proliferate, forming a 
resistant tumor in relapse, accompanying by tumor 
progression [33]. Actually, anticancer drugs may promote 
the emergence of resistance and tumor recurrence [4, 
12]. Thus, in addition to drug cytotoxicity, the cellular 
responses to a given drug must also be considered. We 
need to reach a balance between the cellular response to 
a drug and the cytotoxic effects of a drug. Our results 
clearly illustrate this point by revealing that gemcitabine 
enhanced pancreatic cancer cell invasion and migration 
in a dose-dependent manner, with greater invasion and 
migration in response to higher doses of gemcitabine. 
The drug stress stimulated invasion was altered 
according to the intensity of the drug-related stress. 
Hence, elucidating the mechanisms to counteract the 
early responses of tumor cells to drug stress may provide 
strategy for suppressing drug stress-associated resistance 
while still attacking the cells and may provide further 
predictive information for determining the response of 
tumor cells to a particular drug.
Tumor cells evade or adapt in response to drug 
stress. In this study, we observed increased cell invasion 
after gemcitabine treatment for 24 hours, which enabled 
cancer cells to escape drug-induced cell death; however, 
we did not observe a typical change of EMT markers 
expression (Supplementary Figure S4B). Our results 
revealed another mechanism of stress-associated drug 
resistance that results from a short-term stress escape 
response; the increased invasion capability was the cause, 
not the result, of drug resistance. Similar results were 
also reported by Arora et al., who found that both the 
up-regulation of CXCR4 expression and the subsequent 
increased invasiveness served as counter-defense 
mechanisms against gemcitabine [32]. These protective 
evasion responses permit short-term cancer cell survival 
before the onset of cell death and extend cell viability if 
the environment becomes permissible. However, whether 
the migrated cells can resist further long-term drug 
treatment is unclear. Furthermore, the molecular circuits 
that connect the cross-talk between early stress responses 
and long-term adaptation remain poorly understood.
Gemcitabine, a genotoxic DNA-damaging agent, 
directly incorporates into DNA or inhibits ribonucleotide 
reductase to prevent DNA replication, thus inducing cell 
death and cell cycle arrest. Moreover, gemcitabine has 
been reported to inhibit pancreatic cell invasion at a low 
dose of 50 nM [34, 35] or have no effect at a dose of 100 
nM [36, 37]. However, gemcitabine at a higher dose of 
10 μM in vitro or in a bolus injection at the maximum 
tolerated dose of 500 mg/kg in vivo facilitated cell invasion 
and accelerated metastasis in mice, respectively [32, 38, 
39]. These results suggest that the cellular response to 
short-term, high-dose chemotherapy promotes invasion 
and metastasis, which is consistent with our present 
results. In our study, PANC-1 and MIA PaCa-2 cells were 
treated with 1-10 μM gemcitabine, which significantly 
increased the invasion capacities of both cell lines. The 
doses of 1-10 μM are significantly higher than the IC50 of 
gemcitabine in MIA PaCa-2 cells but are equal to the IC50 
in PANC-1 cells. A relatively lower dose of gemcitabine 
was used in PANC-1 cells than in MIA PaCa-2 cells, but 
a greater increase in invasion was observed in PANC-1 
cells. The different genetic backgrounds of the two cell 
lines potentially explain this difference, i.e., PANC-1 
cells express mutated EGFR, whereas EGFR is wild type 
in MIA PaCa-2 cells. Taken together, both a higher dose 
of gemcitabine and the genetic background of the cells 
contribute to the in vitro active cellular stress response of 
increased invasion.
We previously showed that the cell adhesion 
molecule HAb18G/CD147 stimulates cellular stress 
responses, such as unfold protein response [19], EMT 
[20], autophagy [21], and anoikis resistance [22, 23]. In 
this paper, we report that HAb18G/CD147 is up-regulated 
in response to drug stress and is required for gemcitabine-
enhanced invasion. Furthermore, rather than being a 
cell death signal, HAb18G/CD147 up-regulation was a 
protective pro-survival response. In addition to cancer, 
CD147 has been reported to protect neurons against in 
vitro cholesterol and amyloid-b stress [40], oxidative and 
ischemic injury [41] and focal cerebral ischemia [42]. All 
these studies suggest that CD147 has a cytoprotective 
role in response to various injuries, including drug stress 
and that CD147 may be a stress response protein. To the 
best of our knowledge, the present study is the first to 
demonstrate that CD147 functions in chemoresistance 
partly by actively responding to cellular stress, in addition 
to its roles in regulating hyaluronan signaling [43] and 
ABCG2 cellular localization and dimerization [44].
Regarding the mechanism of CD147 up-regulation, 
our previous publication demonstrated that the HAb18G/
CD147 promoter contains a hypoxia-inducible factor 
response element, which enables increased transcription in 
response to hypoxia [45]. However, in our present study, 
the up-regulation of CD147 occurred at the protein level, 
specifically at the membrane protein level, indicating 
a completely different scenario. As the up-regulation of 
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CD147 occurred as early as 2 hours post-gemcitabine 
treatment, we can reasonably infer that the rapid recycling 
of CD147 to the plasma membrane and impaired 
degradation may contribute to this rapid induction [46]. 
Consequently, CD147 can respond quickly to drug stress 
by influencing cell adhesion and migratory properties. 
The detailed mechanism by which CD147 is rapidly up-
regulated remains under active investigation.
We previously reported that HAb18G/CD147 
promotes pSTAT3-mediated pancreatic cancer progression 
via CD44s [24]. In this study, we show that HAb18G/
CD147 contributes to gemcitabine stress-enhanced 
invasion by activating pSTAT3, indicating a novel role for 
CD147 in STAT3-mediated chemoresistance in addition 
to promoting PDAC. Among the STAT3 upstream 
membrane proteins that may associate with CD147, we 
determined that EGFR was activated in response to short-
term gemcitabine treatment. Therefore, we propose that 
in response to gemcitabine stress, pancreatic cancer cells 
first up-regulate HAb18G/CD147 expression and then 
activate EGFR-STAT3 signaling via phosphorylation 
at tyrosine 705 to promote the transcription of STAT3 
target genes, such as MMP and cyclin D1/survivin, and 
ultimately to increase cell survival and invasion (Figure 
5F). Our previous findings and literature both suggest that 
HAb18G/CD147 activated EGFR signaling in pancreatic 
cancer cells may depend on CD44 [24, 47]. For the 
cellular response to gemcitabine stress, furthermore, we 
actually observed a slightly increase of CD44 expression 
upon gemcitabine treatment, as shown in Supplementary 
Figure S4A. Therefore, the activation of EGFR signaling 
by CD147 in gemcitabine-enhanced invasion process 
possibly depended on CD44 expression.
In human pancreatic cancer, high EGFR expression 
is required for both the initiation and survival of ADM 
(and pancreatic intraepithelial neoplasia [PanIN]) lesions, 
and EGFR ablation restricts the development of PDAC 
[48]. Inhibiting EGFR signaling has also been reported to 
improve the efficacy of gemcitabine in human pancreatic 
tumor xenograft models [49]. Erlotinib, an EGFR kinase 
inhibitor, sensitizes metastatic pancreatic cancer patients to 
gemcitabine; the combination of erlotinib and gemcitabine 
was approved as a therapy for PDAC based on a survival 
benefit of approximately two weeks [50]. However, only 
limited efficacy was shown [51]. Our study may provide 
a strategy for counteracting gemcitabine stress-associated 
resistance by inhibiting EGFR upstream signaling.
In conclusion, our study suggests that pancreatic 
cancer cells actively respond to short-term gemcitabine 
stress by inducing invasion via up-regulating HAb18G/
CD147 and activating downstream EGFR-pSTAT3 
signaling. Our results will be valuable for obtaining a 
better understanding of the flexibility and interplay of 
the balanced biosystem between tumor cells and drug 
stress and the powerful potential of tumor cells to adapt to 
environmental stress. In addition, our results establish that 
inhibiting HAb18G/CD147 before gemcitabine treatment 
may provide a novel combination strategy to overcome 
gemcitabine stress-associated resistance in pancreatic 
cancer.
MATERIALS AND METHODS
Antibodies, drugs and reagents
The following antibodies were used in this study: 
anti-EGFR (Cell Signaling Technology, Danvers, MA), 
anti-STAT3 and anti-vimentin (Proteintech Group Inc, 
Chicago, IL), anti-phospho-EGFR (pY1173) and anti-
phospho-STAT3 (pY705) (Epitomics, Burlingame, CA), 
anti-CD44, anti-SNAI1 and anti-α-tubulin (Santa Cruz 
Biotechnology, Dallas, TX), anti-N-cadherin, goat anti-
mouse DyLight 488 and goat anti-rabbit DyLight 488 
(Thermo Fisher Scientific, Rockford, IL), PE-conjugated 
anti-human CD147 and isotype-matched mouse 
immunoglobulin (Miltenyi Biotec, Auburn, CA), and goat 
anti-rabbit Texas-Red and goat anti-mouse fluorescein 
isothiocyanate (FITC) (Jackson ImmunoResearch, West 
Grove, PA). Goat anti-rabbit horseradish peroxidase 
(HRP), goat anti-mouse HRP, mouse IgG, geneticin 
(G418) and Lipofectamine 2000 transfection reagent 
were purchased from Invitrogen (Carlsbad, CA). The 
anti-mouse HAb18G/CD147 antibody HAb18IgG was 
prepared as previously reported [16].
Recombinant human CyPA was purchased from 
Sigma-Aldrich (St. Louis, MO), puromycin was purchased 
from InvivoGen (San Diego, CA), WP1066 was obtained 
from Calbiochem (Billerica, MA), gemcitabine was 
purchased from Lilly France S.A. (Fegersheim, France), 
and PD153035 and gefitinib were obtained from Selleck 
(Boston, MA).
Cell lines and constructs
The human pancreatic cancer cell lines PANC-1, 
MIA PaCa-2 and the embryonic kidney cell line 
HEK293 were obtained from American Type Culture 
Collection and were cultured in DMEM (HyClone, 
Logan, UT) supplemented with 10% fetal bovine serum 
(FBS, HyClone, Logan, UT). CD147 pLKO.1 lentiviral 
shRNA (A6) was obtained from Open Biosystems. The 
MISSION® Non-Target shRNA Control Vector (pLKO.1-
NTC) was obtained from Sigma-Aldrich. Human CD147 
cDNA was subcloned into the pEGFP-N1 expression 
vector (Clontech, Mountain View, CA) as described 
previously [24].
Establishment of stable cell lines
CD147 lentiviral shRNA or non-target control 
shRNA was introduced into cells using FuGENE 6 
(Roche). CD147/EGFP cDNA and pEGFP control vectors 
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were transfected into HEK293 cells using Lipofectamine 
2000 (Invitrogen) [24]. Knock-down or knock-in cells 
were selected by adding 4-6 μg/mL puromycin or 1 mg/
mL G418 to the culture medium. The silencing or up-
regulation of HAb18G/CD147 expression was verified by 
qPCR, immunoblot and flow cytometry.
RNA interference
Chemically synthesized, double-stranded CD147 
siRNAs were purchased from GenePharma Co., Ltd 
(Shanghai, China). The sequence for CD147 siRNA 
(siCD147) is 5’- GUUCUUCGUGAGUUCCUCtt-3’ [18]. 
Silencer negative control siRNA (sncRNA) was used as a 
negative control.
Cell growth assay
Cells were plated in 24- or 96-well plates; cell 
viability was determined by using a hemocytometer or 
by measuring WST-8 dye absorbance at 450 nm. For 
cytotoxicity assays, cells were exposed to different 
concentrations of gemcitabine. Chemo-sensitivity values 
were expressed as IC50 values. To determine the growth 
inhibition effect of the EGFR inhibitor gefitinib, cells were 
serum-starved for 24 hours before the addition of 80 μM 
gefitinib for one hour followed by a 72-hour treatment 
with 100 nM CyPA. The results are presented as relative 
cell growth inhibition normalized to their individual 
controls. To determine the effect of CD147 knock-down 
or knock-in on gefitinib-mediated growth inhibition, NTC 
or A6 cells were treated with 80 μM gefitinib for 48 hours 
and then analyzed. The cell growth inhibition ratio of 
gefitinib is indicated with an arrow in the figures.
In vitro migration and invasion assay
In vitro migration and invasion assays were 
performed using 24-well BioCoat Matrigel Invasion 
Chambers (BD Biosciences Cat No. 354480) containing 
BD Falcon Cell Culture Inserts with an 8-μm-diameter 
pore size PET membrane that were coated without 
(migration) or with (invasion) Matrigel matrix. To perform 
the assays, the inserts containing Matrigel were hydrated 
using 500 μL of warm culture medium without serum 
at 37°C for 2 hours. After hydration, the medium was 
removed from the chambers, and the inserts were placed 
on top of each well containing 3-8×104 cells pre-treated 
with gemcitabine or WP1066. Media containing 10% 
FBS was added to the lower chamber, and the cells were 
incubated for 16 hours. Cells that remained on the upper 
surface of the insert membrane were completely removed 
with a cotton swab. Cells that had migrated or invaded 
through the membrane/Matrigel to the bottom of the insert 
were fixed, stained with 0.2% crystal violet and imaged. 
The invasive potential of the cells was determined by 
counting the number of cells that had invaded to the lower 
surface of the filter in 10 different areas using a Nikon 
ECLIPSE Ti inverted light microscope (Pudong New 
District, Shanghai, China). Each assay was performed in 
triplicate in three separate experiments.
Flow cytometry analysis
For the flow cytometric analysis, 106 cells were 
incubated with FITC-conjugated anti-human CD147 
antibody in Hank’s Balanced Salt Solution (HBSS, Gibco) 
containing 2% FBS at 4°C for 30 min. Isotype-matched 
mouse immunoglobulin served as the control. Samples 
were analyzed using a FACS Calibur Flow Cytometer and 
CellQuest software (BD Biosciences, San Jose, CA).
As for flow cytometry analysis of EMT marker 
staining, cells with or without gemcitabine treatment were 
blocked with 1% BSA in PBS on ice for 30 min. The 
cells were then incubated on ice with individual antibody 
N-cadherin (1:100), SNAI1 (1:100), Vimentin (1:100) 
for 1 h. After washing twice with PBS, goat anti-mouse 
DyLight 488 or goat anti-rabbit DyLight 488 at a dilution 
of 1:200 were incubated for another 30 min. Finally, cells 
were suspended in PBS containing 2% FBS, and analyzed.
Western blot analysis
Whole cell extracts from cultured cells were 
prepared by adding phos-RIPA lysis buffer (1 M Tris-
HCl (pH 7.5), 5 M NaCl, 0.01% NP-40, 0.5 M EGTA, 
and 10% SDS) supplemented with Halt phosphatase 
inhibitor (Thermo Fisher Scientific, Rockford, IL) and 
complete protease inhibitor cocktail (Roche, Indianapolis, 
IN) to the cell monolayer. Proteins were separated on 10% 
polyacrylamide gels and transferred to PVDF membranes. 
Membranes were blocked in 5% skim milk for 1 hour. 
Subsequently, the membranes were incubated with each 
individual antibody overnight at 4°C and then with 
horseradish peroxidase-conjugated anti-mouse or anti-
rabbit IgG for 2 hours. Finally, signals were developed 
using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Fisher Scientific, Rockford, IL). To demonstrate 
equal loading, membranes were stripped and reprobed 
with a monoclonal antibody against b-actin or a-tubulin.
Quantitative real-time PCR (qPCR)
Total RNA extraction and cDNA synthesis were 
performed as previously described [9]. qPCR amplification 
was performed using the Stratagene Mx3005P Multiplex 
quantitative PCR system (Agilent Technologies, Santa 
Clara, CA) with gene-specific primers for HAb18G/CD147: 
forward: 5’-TCGCGCTGCTGGGCACC-3’; reverse: 
5’-TGGCGCTGTCATTCAAGGA-3’. Genes of interest 
were normalized to the housekeeping gene 18S RNA: 
forward: 5’-CGCCGCTAGAGGTGAAATTC-3’; reverse: 
5’-TTGGCAAATGCTTTCGCTC-3’. Relative mRNA 
levels are presented as unit values of 2−ΔCt = 2−(Ct (HKG) − Ct (GOI)).
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Immunofluorescence staining
Cells grown on chambered cover slips were fixed, 
blocked and probed with the anti-HAb18G/CD147 
antibody HAb18IgG and anti-EGFR antibody. The 
signals were detected with fluorochrome-conjugated 
FITC and Texas Red. Cover slips were counterstained 
with 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen) 
to visualize the nuclei. Cell images were observed 
and acquired using a fluorescence microscope (Nikon 
ECLIPSE Ti, Pudong New District, Shanghai, China).
Immunohistochemistry staining
TMA staining was performed using standard 
immunohistochemical staining procedures. To confirm 
the specificity of the primary antibodies, tissue sections 
were incubated with control mouse IgG in the absence of 
primary antibody. The number of positively stained cells 
and the intensity of positive staining on epithelium cells 
were independently scored by 2 pathologists in a blinded 
manner. The percentage of positive cells was scored as 
follows: 0, 1-25%, 26-75% and > 75%. The intensity of 
positive immunostaining was graded by an experienced 
pancreatic pathologist in a blinded manner and was 
classified into four categories: 0 (no visible staining), 
1 (light brown staining), 2 (medium brown staining), 
and 3 (dark brown staining), with the same intensity 
covering more than 75% of the stained area. For tissue 
samples with surface-bound HAb18G/CD147 and EGFR, 
samples with no staining were classified as negative or 
no staining; samples with 1+ staining in ≤ 50% of cells 
or 2+ staining in ≤ 25% of cells were classified as light 
staining; samples with 1+ staining in > 50% of cells, 2+ 
staining in 26-75% of cells or 3+ staining in ≤ 25% of cells 
were classified as intermediate staining; and samples with 
2+ staining in > 75% of cells or 3+ staining in > 25% of 
cells were classified as intense staining. For the statistical 
analysis, the stained tumor tissues were divided into two 
groups: the low-expression group and the high-expression 
group. The low-expression group included cases with a 
negative staining intensity score; the high-expression 
group included cases with staining intensity scores of light 
staining, intermediate staining and intense staining.
Patient samples
Fresh and paraffin-embedded pancreatic tumor 
and adjacent non-tumor tissues from pancreatic cancer 
patients were obtained from the University of Michigan 
Comprehensive Cancer Center (UMCCC) Histology Core 
according to an IRB-approved human protocol (H7094). 
TMAs from 179 patient tissues were obtained from the 
UMCCC Histology Core for the analysis of HAb18G/
CD147 and EGFR expression. Two different recipient 
paraffin blocks were generated: “control tissue array” and 
“tumor tissue array”. The “control tissue array” included 48 
cases of normal pancreatic tissue and 7 cases of pancreatitis; 
the “tumor tissue array” included 2 cases of PanIN, 4 cases 
of cystadenoma, 15 cases of intraductal papillary mucinous 
neoplasm (IPMN) and 103 cases of PDAC.
Animal studies
All animal experiments were performed in 
accordance with Institutional Animal Care and Use 
Committee approved protocols. For the localized 
subcutaneous xenograft mouse model, 1×106 MIA 
PACa-2 NTC or CD147 knock-down A6 cells in 0.2mL 
DMEM were inoculated into five- to six-week-old 
female nude mice subcutaneously. When tumors reached 
a mean volume of 100mm3, mice were randomized 
into four groups (n=5 mice per group). Tumor volume 
was measured using vernier calipers twice a week and 
the tumor volume was calculated using the formula 
described by us previously [24]. Gemcitabine (100 mg/
kg) or saline (control group) was administered as a single 
intraperitoneal injection. 24 hours later, the subcutaneous 
tumors were harvested from the flanks of the mouse by 
blunt dissection. Tumors were mechanically minced and 
incubated at 37°C for 2 hours in the cell dissociation 
buffer (DMEM supplemented with 10% FBS, penicillin-
streptomycin (Invitrogen, Carlsbad, CA), 200 U/mL 
collagenase type IV (Invitrogen, Carlsbad, CA), and 0.6 
U/mL dispase (Sigma-Aldrich, St. Louis, MO). The cell 
suspension was then passed through a 70-μm filter (BD 
Biosciences, San Jose, CA) and the cells were collected 
for the invasion assay [52].
Statistical analysis
All the data are presented as the mean ± SD 
of triplicate values from three separate experiments. 
Independent Student’s t tests or one-way ANOVAs were 
used to compare the continuous variables between 2 
groups or more than 2 groups, and categorical variables 
were compared using the χ2 test. Spearman rank 
correlation was conducted to analyze the correlation 
between the expression of HAb18G/CD147 and EGFR 
mRNA. Statistical analyses were performed using SPSS 
13.0 (IBM) and Prism 5.0 (GraphPad). *P < 0.05 was 
considered statistically significant.
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